Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05401786 | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC(RAD-IO) | active not recruiting | Phase 2 | 54 | The Netherlands Cancer InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05904379 | AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 233 | AkesoINDUSTRY | 1 | Mar 9, 2026 |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT02716116 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 334 | TakedaINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT02422381 | MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 16 | Providence Health & ServicesOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)(IGNYTE) | active not recruiting | Phase 2 | 340 | Replimune, Inc.INDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT05714891 | Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 4 | Canadian Cancer Trials GroupNETWORK | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04395677 | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | active not recruiting | Phase 2 | 173 | Nuvation Bio Inc.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04884282 | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)(COMBI-TED) | active not recruiting | Phase 2 | 105 | Fondazione Ricerca TraslazionaleOTHER | 3 | Feb 6, 2026 | clinicaltrials |
| NCT03808662 | Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung | active not recruiting | Phase 2 | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT04223596 | Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients(CUBIK) | active not recruiting | Phase 2 | 33 | Fundación GECPOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06984588 | A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 450 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07005336 | A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 150 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03974022 | Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | active not recruiting | Phase 1 / Phase 2 | 315 | Dizal PharmaceuticalsINDUSTRY | 13 | Jan 29, 2026 | clinicaltrials |
| NCT05340309 | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 5 | University of Southern CaliforniaOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05206812 | Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | active not recruiting | Phase 2 | 25 | Yonsei UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05786430 | Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib(LUCAS) | active not recruiting | Phase 2 | 87 | Yonsei UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05816252 | A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | active not recruiting | Phase 2 | 356 | Klus Pharma Inc.INDUSTRY | 6 | Jan 27, 2026 | clinicaltrials |
| NCT05601973 | Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI(AMAZE-lung) | active not recruiting | Phase 2 | 60 | ETOP IBCSG Partners FoundationNETWORK | 6 | Jan 21, 2026 | clinicaltrials |
| NCT04743505 | Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 27 | Washington University School of MedicineOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05740943 | Induction Lorlatinib in Stage III Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 48 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06879717 | A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients(PULMO-01) | active not recruiting | Phase 1 / Phase 2 | 45 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05089916 | Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study(ROSE) | active not recruiting | Phase 2 | 42 | AIO-Studien-gGmbHOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients(RAMP203) | active not recruiting | Phase 1 / Phase 2 | 153 | Verastem, Inc.INDUSTRY | 6 | Jan 12, 2026 | clinicaltrials |
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC(TRUST-II) | active not recruiting | Phase 2 | 217 | Nuvation Bio Inc.INDUSTRY | 9 | Jan 7, 2026 | clinicaltrials |
| NCT02638090 | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 120 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07274761 | Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. | active not recruiting | Phase 2 | 24 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04940325 | Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer(ICARUS-LUNG01) | active not recruiting | Phase 2 | 100 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05781308 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy(ADAPTABLE) | active not recruiting | Phase 2 | 156 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT05200481 | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)(MP-ALK) | active not recruiting | Phase 2 | 110 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 270 | AbbVieINDUSTRY | 26 | Nov 5, 2025 | clinicaltrials |
| NCT03667820 | Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC | active not recruiting | Phase 2 | 41 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03334617 | Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy(HUDSON) | active not recruiting | Phase 2 | 528 | AstraZenecaINDUSTRY | 8 | Oct 27, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT00977470 | Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations | active not recruiting | Phase 2 | 76 | Massachusetts General HospitalOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04931654 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | active not recruiting | Phase 1 / Phase 2 | 136 | AstraZenecaINDUSTRY | 10 | Oct 9, 2025 | clinicaltrials |
| NCT05949619 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05020457 | SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. | active not recruiting | Phase 2 | 69 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05020769 | SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. | active not recruiting | Phase 2 / Phase 3 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06448910 | Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC | active not recruiting | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05880706 | A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 198 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 12, 2026source: clinicaltrials